GlassScriptPhysician profile
Glenn O Archibald
NPI 1316947450
$23,567.50
in general payments reported to CMS, 2019-2025
35 companies · $4,857 in 2025
The $4,857 reported for 2025 was more than what 94% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,790 · 2020: $1,709 · 2021: $2,078 · 2022: $3,783 · 2023: $4,502 · 2024: $4,848 · 2025: $4,857.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,982.20 |
| Education | $225.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,997.04 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Alkermes, INC. | $2,518.66 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,984.61 | 2021-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $1,869.47 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $1,633.12 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $1,609.96 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Vanda Pharmaceuticals INC. | $1,507.51 | 2019-2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $1,179.63 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $1,159.16 | 2019-2025 | Spravato, Invega Sustenna |
| Lundbeck LLC | $742.27 | 2019-2025 | Rexulti, Abilify Maintena |
| Corium, LLC | $742.12 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $728.62 | 2019-2025 | Aplenzin, Wellbutrin |
| Ironshore Pharmaceuticals INC. | $521.95 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $465.29 | 2023-2025 | Auvelity, Sunosi |
| Allergan, INC. | $416.90 | 2019-2020 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $313.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $282.32 | 2024-2025 | Cobenfy |
| Neuronetics, INC. | $257.18 | 2025 | Neurostar Tms Therapy System |
| Almatica Pharma LLC | $243.87 | 2022-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $229.34 | 2019-2022 | |
| Indivior INC. | $201.65 | 2019-2025 | Sublocade |
| Eisai INC. | $200.99 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $139.49 | 2022-2025 | |
| Tris Pharma INC | $124.01 | 2021-2025 | Dyanavel Xr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $106.54 | 2025 | Rejoyn |
| Orexo US, INC. | $59.89 | 2021-2024 | Zubsolv |
| Jazz Pharmaceuticals INC. | $57.57 | 2021 | |
| Idorsia Pharmaceuticals US INC | $51.90 | 2023-2024 | Quviviq |
| Harmony Biosciences LLC | $39.61 | 2021-2023 | Wakix |
| Merck Sharp & Dohme LLC | $36.46 | 2021 | |
| Neos Therapeutics, LP | $35.35 | 2019 | |
| Collegium Pharmaceutical, INC. | $34.72 | 2025 | Jornay Pm |
| Arbor Pharmaceuticals, INC. | $29.54 | 2019 | |
| Shire North American Group INC | $24.86 | 2019 | |
| Noven Pharmaceuticals, INC. | $22.48 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Glenn Archibald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.